Last reviewed · How we verify
NCT06199141: MDR-ECMO
Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)
trial in Respiratory Distress Syndrome, Adult in 279 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | University of Padova |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 279 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Italy |
Conditions studied
- Respiratory Distress Syndrome, Adult — all drugs for Respiratory Distress Syndrome, Adult →
- Multi-antibiotic Resistance — all drugs for Multi-antibiotic Resistance →
Sponsor
University of Padova
Who can join
18 and older, any sex, with Respiratory Distress Syndrome, Adult or Multi-antibiotic Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a life-support technique used in patients with most severe acute respiratory distress syndrome (ARDS). ARDS is a life-threatening form of respiratory failure associated with a mortality rate of approximately 40-45%.Despite several studies confirming a real benefit of the use of ECMO in patients with ARDS who are unresponsive to conventional management, ECMO is still a complex and costly treatment that can be exposed to potential complications, such as nosocomial infections (NI).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06199141
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Distress Syndrome, Adult
Currently open trials in the same condition.
- NCT06203405 — The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Ra · NA · recruiting
- NCT04545424 — Trial of Therapeutic Hypothermia in Patients With ARDS · Phase 2 · recruiting
- NCT03368092 — Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma · Phase 3 · recruiting
- NCT03709199 — Long Term Follow up of Children Enrolled in the REDvent Study · active not recruiting
Other University of Padova trials
Trials by the same sponsor.
- NCT07435064 — NURsing-led FRAILty Prevention and Care · NA · not yet recruiting
- NCT07283354 — Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia · not yet recruiting
- NCT07259460 — Effects of Dexmedetomidine Target Controlled Infusion on Patient State Index Values and Electroencephalographic Spectrum · recruiting
- NCT07385118 — Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise · NA · completed
- NCT07259291 — Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06199141 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Padova
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06199141.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing